The MYC oncogene — the grand orchestrator of cancer growth and immune evasion

R Dhanasekaran, A Deutzmann… - Nature reviews Clinical …, 2022 - nature.com
The MYC proto-oncogenes encode a family of transcription factors that are among the most
commonly activated oncoproteins in human neoplasias. Indeed, MYC aberrations or …

ERK signalling: a master regulator of cell behaviour, life and fate

H Lavoie, J Gagnon, M Therrien - Nature reviews Molecular cell biology, 2020 - nature.com
The proteins extracellular signal-regulated kinase 1 (ERK1) and ERK2 are the downstream
components of a phosphorelay pathway that conveys growth and mitogenic signals largely …

The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy

J Yuan, X Dong, J Yap, J Hu - Journal of hematology & oncology, 2020 - Springer
Cancer is characterized as a complex disease caused by coordinated alterations of multiple
signaling pathways. The Ras/RAF/MEK/ERK (MAPK) signaling is one of the best-defined …

RAF-MEK-ERK pathway in cancer evolution and treatment

R Ullah, Q Yin, AH Snell, L Wan - Seminars in cancer biology, 2022 - Elsevier
Abstract The RAF-MEK-ERK signaling cascade is a well-characterized MAPK pathway
involved in cell proliferation and survival. The three-layered MAPK signaling cascade is …

MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies

SE Ahmadi, S Rahimi, B Zarandi, R Chegeni… - Journal of hematology & …, 2021 - Springer
MYC oncogene is a transcription factor with a wide array of functions affecting cellular
activities such as cell cycle, apoptosis, DNA damage response, and hematopoiesis. Due to …

Target gene-independent functions of MYC oncoproteins

A Baluapuri, E Wolf, M Eilers - Nature Reviews Molecular Cell Biology, 2020 - nature.com
Oncoproteins of the MYC family are major drivers of human tumorigenesis. Since a large
body of evidence indicates that MYC proteins are transcription factors, studying their function …

The role of CDC25C in cell cycle regulation and clinical cancer therapy: a systematic review

K Liu, M Zheng, R Lu, J Du, Q Zhao, Z Li, Y Li… - Cancer Cell …, 2020 - Springer
One of the most prominent features of tumor cells is uncontrolled cell proliferation caused by
an abnormal cell cycle, and the abnormal expression of cell cycle-related proteins gives …

[HTML][HTML] KRAS-Mutant non-small cell lung cancer: From biology to therapy

I Ferrer, J Zugazagoitia, S Herbertz, W John… - Lung cancer, 2018 - Elsevier
In patients with non-small cell lung cancer (NSCLC), the most frequent oncogene driver
mutation in Western countries is Kirsten rat sarcoma viral oncogene homolog (KRAS), and …

Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo

C Dubiella, BJ Pinch, K Koikawa, D Zaidman… - Nature chemical …, 2021 - nature.com
The peptidyl-prolyl isomerase, Pin1, is exploited in cancer to activate oncogenes and
inactivate tumor suppressors. However, despite considerable efforts, Pin1 has remained an …

MYC deregulation in primary human cancers

M Kalkat, J De Melo, KA Hickman, C Lourenco… - Genes, 2017 - mdpi.com
MYC regulates a complex biological program by transcriptionally activating and repressing
its numerous target genes. As such, MYC is a master regulator of many processes, including …